• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Request Free Sample ×

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor

    Biomarker Market

    ID: MRFR/HC/1409-CR
    200 Pages
    Rahul Gotadki
    July 2025

    Biomarkers Market Research Report By Type (Predictive Biomarkers, Diagnostic Biomarkers, Prognostic Biomarkers, Pharmacodynamic Biomarkers, Research Biomarkers), By Application (Oncology, Cardiovascular, Neurology, Infectious Diseases, Autoimmune Diseases), By Technology (Omics Technologies, Imaging Technologies, Bioinformatics, Mass Spectrometry, PCR Technologies), By End-use (Pharmaceutical Companies, Clinical Laboratories, Research Institutions, Diagnostic Laboratories), and By Regional (North America, Europe, South America, Asia Pacific,...

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Biomarker Market Infographic
    Purchase Options
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0

    Biomarker Market Summary

    The global biomarkers market is projected to grow from 43.1 USD billion in 2024 to 85.7 USD billion by 2035, reflecting a robust growth trajectory.

    Key Market Trends & Highlights

    Biomarkers Key Trends and Highlights

    • The market is expected to experience a compound annual growth rate (CAGR) of 6.45 percent from 2025 to 2035.
    • By 2035, the global biomarkers market is anticipated to reach a valuation of 85.7 USD billion, nearly doubling from its 2024 valuation.
    • In 2024, the market is valued at 43.1 USD billion, indicating a strong foundation for future growth.
    • Growing adoption of personalized medicine due to increasing prevalence of chronic diseases is a major market driver.

    Market Size & Forecast

    2024 Market Size 43.1 (USD Billion)
    2035 Market Size 85.7 (USD Billion)
    CAGR (2025-2035) 6.45%

    Major Players

    Novartis, Thermo Fisher Scientific, Gilead Sciences, Pfizer, Biogen, Merck & Co, Agilent Technologies, Amgen, Qiagen, Hoffmann-La Roche, Johnson & Johnson, Bristol-Myers Squibb, Illumina, AbbVie

    Biomarker Market Trends

    As chronic illnesses become more common and tailored medication becomes more important, the Biomarkers Market is expanding significantly. The need for efficient diagnostic instruments is driving biomarker discovery advancements, which in turn is resulting in the creation of cutting-edge technologies like proteomics and high-throughput genomics.

    Market expansion is being aided by government programs supporting healthcare research and development and financing biomarker-based investigations. Faster approvals of biomarker diagnostics are another benefit of improved regulatory frameworks, which is driving business expansion.

    Collaborations between pharmaceutical firms and academic institutions might further investigate opportunities in the Biomarkers Market. These collaborations can expedite the medication development process and improve the discovery of new biomarkers.

    Furthermore, the application of big data analytics and artificial intelligence to biomarker research is opening up possibilities for quicker and more effective data interpretation. Companion diagnostics, which are essential for targeted therapy in cancer, are receiving more attention, according to recent developments.

    This development, which enables customized therapies based on unique patient profiles, is consistent with the worldwide movement towards precision medicine. Additionally, liquid biopsies are becoming a powerful tool for illness monitoring and identification since they are less intrusive and offer real-time information on how a disease is progressing.

    In conclusion, the dynamic drivers, substantial collaborative potential, and cutting-edge trends that emphasize precision healthcare and better patient outcomes define the Biomarkers Market.

    The Global Biomarkers Market is poised for transformative growth, driven by advancements in precision medicine and the increasing demand for personalized healthcare solutions.

    U.S. National Institutes of Health (NIH)

    Biomarker Market Drivers

    Market Growth Projections

    The Global Biomarkers Market Industry is poised for substantial growth, with projections indicating a rise from 43.1 USD Billion in 2024 to 85.7 USD Billion by 2035. This growth trajectory, characterized by a CAGR of 6.45% from 2025 to 2035, reflects the increasing recognition of biomarkers in various therapeutic areas. The market expansion is anticipated to be driven by factors such as technological advancements, rising healthcare expenditures, and the growing prevalence of chronic diseases. As the industry evolves, stakeholders are likely to explore new opportunities in biomarker research, development, and commercialization, further solidifying the market's position in the global healthcare landscape.

    Advancements in Genomic Technologies

    Technological advancements in genomics and proteomics are significantly influencing the Global Biomarkers Market Industry. Innovations such as next-generation sequencing and CRISPR technology enhance the ability to identify and validate biomarkers with greater precision. These advancements facilitate the development of targeted therapies, which are increasingly favored in clinical settings. As the market evolves, the integration of artificial intelligence in biomarker discovery is also emerging, potentially streamlining the research process. The anticipated growth from 43.1 USD Billion in 2024 to 85.7 USD Billion by 2035, with a CAGR of 6.45% from 2025 to 2035, indicates a robust trajectory fueled by these technological breakthroughs.

    Rising Prevalence of Chronic Diseases

    The increasing incidence of chronic diseases such as cancer, diabetes, and cardiovascular disorders drives the Global Biomarkers Market Industry. As of 2024, the market is valued at 43.1 USD Billion, reflecting a growing demand for biomarkers in early diagnosis and personalized medicine. Biomarkers play a crucial role in identifying disease progression and treatment efficacy, which is essential for managing chronic conditions. The World Health Organization indicates that chronic diseases account for approximately 71 percent of global deaths, underscoring the urgent need for innovative diagnostic tools. This trend is likely to propel the market further as healthcare systems seek more effective solutions.

    Growing Demand for Personalized Medicine

    The shift towards personalized medicine is a key driver of the Global Biomarkers Market Industry. Patients and healthcare providers increasingly prefer tailored treatment approaches that consider individual genetic profiles and disease characteristics. Biomarkers serve as critical tools in this paradigm, enabling the identification of patient subgroups that may respond differently to therapies. This trend is reflected in the market's projected growth from 43.1 USD Billion in 2024 to 85.7 USD Billion by 2035. The emphasis on personalized treatment strategies is likely to spur further research and development in biomarker applications, enhancing their role in improving patient outcomes.

    Regulatory Support for Biomarker Development

    Regulatory agencies are increasingly recognizing the importance of biomarkers in drug development and patient management, which positively impacts the Global Biomarkers Market Industry. Initiatives aimed at streamlining the approval process for biomarker-based diagnostics and therapeutics are being implemented. The U.S. Food and Drug Administration has established guidelines that facilitate the use of biomarkers in clinical trials, thereby encouraging their integration into routine practice. This regulatory support not only accelerates the development of new biomarkers but also enhances their credibility in clinical settings. Consequently, the market is likely to benefit from a more favorable regulatory landscape, fostering innovation and adoption.

    Increased Investment in Research and Development

    The Global Biomarkers Market Industry is witnessing heightened investment in research and development, driven by both public and private sectors. Governments and pharmaceutical companies are allocating substantial resources to biomarker research, recognizing their potential to revolutionize diagnostics and therapeutics. This influx of funding supports the discovery of novel biomarkers and the validation of existing ones, enhancing their clinical utility. For instance, the National Institutes of Health has prioritized biomarker research in its funding initiatives, which may lead to significant advancements in personalized medicine. As a result, the market is expected to expand, reflecting the growing commitment to innovative healthcare solutions.

    Market Segment Insights

    Biomarkers Market Type Insights 

    The Biomarkers Market experienced substantial growth, particularly within the Type segment, which included Predictive Biomarkers, Diagnostic Biomarkers, Prognostic Biomarkers, Pharmacodynamic Biomarkers, and Research Biomarkers.

    Predictive Biomarkers played a crucial role, with a market valuation of 8.64 USD Billion in 2024, projected to grow to 17.2 USD Billion by 2035, indicating their ability to forecast disease progression and treatment response, thus being a vital component in personalized medicine strategies.

    The Diagnostic Biomarkers segment was noteworthy as well, valued at 12.09 USD Billion in 2024, and anticipated to rise to 24.5 USD Billion in 2035, emphasizing their critical function in accurate disease detection, which was essential for effective therapy initiation and management.

    Prognostic Biomarkers also held significance in the market, showing a valuation of 7.98 USD Billion in 2024 and an expected increase to 16.5 USD Billion by 2035, as they assisted in predicting the outcome of diseases, thus guiding therapeutic decisions and patient management.

    Moreover, Pharmacodynamic Biomarkers, valued at 6.44 USD Billion in 2024 and destined for 13.3 USD Billion by 2035, were vital for understanding the pharmacological responses of treatments, ensuring that medications were appropriately tailored to individual responses.

    Biomarkers Market Application Insights

    The market segmentation emphasizes various applications, with Oncology being a prominent field due to the rising incidence of cancer globally, necessitating innovative biomarker solutions for early detection and treatment personalization. Cardiovascular applications are also critical, addressing the global burden of heart diseases which necessitate innovative biomarker techniques for diagnosis and risk assessment.

    Further, the Neurology segment showcases growth opportunities, especially in understanding complex conditions such as Alzheimer's disease, while Infectious Diseases remain a vital focus area in the face of emerging global health threats, especially since rapid diagnostics are in high demand.

    Additionally, Autoimmune Diseases represent a significant segment, highlighting the need for effective biomarkers to distinguish between various autoimmune conditions for tailored treatment strategies. The ongoing trends in diagnostics and personalized therapy support the continuous development seen across these applications.

    The diversity within the Biomarkers Market segmentation showcases a robust landscape ripe with opportunities for advancements and innovations.

    Biomarkers Market Technology Insights

    The Technology segment of the Biomarkers Market has been a pivotal area, showcasing robust growth and innovation. Within this segment, Omics Technologies have emerged as a key player, driving discoveries in genomics and proteomics, thus enhancing personalized medicine approaches.

    Imaging Technologies are crucial for visualizing biological processes, significantly aiding in diagnostics and disease monitoring. Meanwhile, Bioinformatics facilitates the analysis of complex biological data, integrating computational tools to support decision-making in Research and Development and clinical applications.

    Mass Spectrometry is recognized for its precision in biomarker identification and quantification, making it indispensable in both clinical and research settings. PCR Technologies remain essential due to their rapid and reliable amplification of DNA, serving as a backbone in various applications in diagnostics.

    The collective impact of these technologies is supported by a growing emphasis on precision medicine and increased investments in healthcare initiatives globally, contributing to the evolution and expansion of the Biomarkers Market.

    Biomarkers Market End-use Insights

    The growth is accompanied by a segmentation that highlights key End-use categories such as Pharmaceutical Companies, Clinical Laboratories, Research Institutions, and Diagnostic Laboratories. Pharmaceutical Companies play a crucial role, utilizing biomarkers for drug discovery and development, thereby impacting patient safety and effectiveness.

    Meanwhile, Clinical Laboratories are essential for performing biomarker tests and diagnostics, contributing significantly to healthcare outcomes. Research Institutions leverage biomarkers to advance scientific knowledge and innovation in disease management.

    Diagnostic Laboratories are vital in providing accurate and timely results in disease detection, leveraging advancements in biomarker technologies. The overall Biomarkers Market data reveals a strong trend toward personalized medicine, driven by increasing healthcare demand and technological advancements.

    Additionally, while the market faces challenges such as regulatory hurdles and the complexity of biomarker validation, opportunities abound in enhancing precision medicine and expanding the scope of biomarker applications across various diseases.

    As the industry evolves, the continuous striving for improved diagnostic and therapeutic options remains a central theme in the Biomarkers Market statistics and growth trajectory.

    Get more detailed insights about Biomarkers Market Research Report - Global Forecast till 2035

    Regional Insights

    The Biomarkers Market experienced substantial growth across various regions. North America led the market, holding a significant position with a valuation of 18.5 USD Billion, expected to grow to 37.5 USD Billion by 2035, reflecting its dominance in research and innovation.

    Europe followed closely with a value of 12.5 USD Billion in 2024, anticipated to reach 25.5 USD Billion, supported by advancements in healthcare and regulatory frameworks. The Asia Pacific region accounted for 7.5 USD Billion in 2024, growing to 15.0 USD Billion, driven by increasing healthcare expenditure and a rising population.

    South America, with a market value of 2.5 USD Billion, is projected to grow to 5.0 USD Billion as healthcare access improves. The Middle East and Africa segment was valued at 2.0 USD Billion, expected to reach 3.7 USD Billion, influenced by growing awareness of personalized medicine.

    These regional insights emphasized the Biomarkers Market's segmentation and highlighted the opportunities for growth in different geographical areas, reflecting trends in healthcare advancements and the demand for innovative solutions.

    Biomarkers Market Regional Insights

    Source: Primary Research, Secondary Research, Market Research Future Database and Analyst Review

    Key Players and Competitive Insights

    The Biomarkers Market has evolved significantly over the last few years, driven by advancements in technology and increasing demand for personalized medicine. Competitive insights in this market reveal a landscape filled with collaboration, innovation, and strategic partnerships among key players.

    Companies are leveraging research and development to enhance their product offerings and maintain their competitive edge. The market is characterized by various segments based on types, applications, and countries, leading to diverse competition and strategic positioning.

    The emphasis on diagnostic solutions, drug development, and targeted therapies has stimulated growth, pushing major players to adopt aggressive marketing and distribution strategies tailored to different geographic regions.

    Novartis has established a substantial presence in the Biomarkers Market through its robust pipeline of biomarker development initiatives. The company focuses on integrating biomarkers into its drug discovery processes to enhance patient selection, improve treatment outcomes, and minimize adverse effects.

    The strengths of Novartis in this domain lie in its extensive research capabilities, collaborations with academic institutions and biotechnology firms, and a strong portfolio of innovative therapies. Novartis's commitment to advancing biomarker research underscores its role in developing precision medicine, amplifying its influence in the global healthcare landscape.

    Its strategic focus on rare diseases and oncology has positioned the company as a leader in utilizing biomarkers for therapeutic advancements, contributing significantly to its overall growth and market competitiveness.

    Thermo Fisher Scientific plays a crucial role in the Biomarkers Market, primarily known for its comprehensive range of analytical instruments, reagents, and consumables that support biomarker discovery and validation.

    The company’s significant strengths include its extensive product portfolio designed for biomarker research, including technologies for gene expression analysis, mass spectrometry, and next-generation sequencing.

    Thermo Fisher Scientific has made strategic moves through a series of mergers and acquisitions to expand its capabilities and enhance market presence globally. These integrations have allowed the company to offer integrated solutions that streamline biomarker research, thereby increasing efficiency and reliability in biopharmaceutical applications.

    Its commitment to innovation and customer support ensures Thermo Fisher Scientific remains a vital contributor to the evolving landscape of biomarkers, reinforcing its competitive stance within the industry on a global scale.

    Key Companies in the Biomarker Market market include

    Industry Developments

    The Elecsys PRO-C3 test, created in partnership with Nordic Bioscience, was approved by the FDA in May 2025 by F. Hoffmann-La Roche Ltd. to evaluate the degree of liver fibrosis in patients with steatotic liver disease linked to metabolic dysfunction.

    Roche also introduced the VENTANA MET (SP44) RxDx Assay in May 2025, which is intended to determine which patients with non-small cell lung cancer are suitable for targeted MET inhibitor treatments. By completing the purchase of SYNLAB's clinical diagnostics business in Spain in April 2025, Eurofins Scientific greatly increased its capacity for molecular diagnostics and biomarker validation.

    Ignite Biomedical and Liquid Biosciences formed a strategic alliance in April 2025 to leverage AI-driven bioinformatics systems to find and verify new biomarkers for substance use disorders. Thermo Fisher Scientific and the UK Biobank Pharma proteome Project joined forces in January 2025 to fund the biggest proteome project in the world devoted to biomarker validation and development.

    To enhance early identification and risk stratification in Alzheimer's disease, QIAGEN and Eli Lilly announced in September 2024 that they would be working together to create a QIAstat-Dx in vitro diagnostic panel for APOE genotyping.

    Future Outlook

    Biomarker Market Future Outlook

    The Global Biomarkers Market is projected to grow at a 6.45% CAGR from 2024 to 2035, driven by advancements in personalized medicine, increased R&D investments, and rising prevalence of chronic diseases.

    New opportunities lie in:

    • Develop innovative biomarker-based diagnostics for early disease detection.
    • Leverage AI and machine learning to enhance biomarker discovery processes.
    • Expand partnerships with pharmaceutical companies for biomarker-driven drug development.

    By 2035, the Global Biomarkers Market is expected to reach unprecedented levels, reflecting robust growth and innovation.

    Market Segmentation

    Biomarkers Market Type Outlook

    • Predictive Biomarkers
    • Diagnostic Biomarkers
    • Prognostic Biomarkers
    • Pharmacodynamic Biomarkers
    • Research Biomarkers

    Biomarkers Market End-use Outlook

    • Pharmaceutical Companies
    • Clinical Laboratories
    • Research Institutions
    • Diagnostic Laboratories

    Biomarkers Market Regional Outlook

    • North America
    • Europe
    • South America
    • Asia Pacific
    • Middle East and Africa

    Biomarkers Market Technology Outlook

    • Omics Technologies
    • Imaging Technologies
    • Bioinformatics
    • Mass Spectrometry
    • PCR Technologies

    Biomarkers Market Application Outlook

    • Oncology
    • Cardiovascular
    • Neurology
    • Infectious Diseases
    • Autoimmune Diseases

    Report Scope

    Report Attribute/Metric

    Details

    Market Size 2023

    40.46(USD Billion)

    Market Size 2024

    43.08(USD Billion)

    Market Size 2035

    85.7(USD Billion)

    Compound Annual Growth Rate (CAGR)

    6.45% (2025 - 2035)

    Report Coverage

    Revenue Forecast, Competitive Landscape, Growth Factors, and Trends

    Base Year

    2024

    Market Forecast Period

    2025 - 2035

    Historical Data

    2019 - 2024

    Market Forecast Units

    USD Billion

    Key Companies Profiled

    Novartis, Thermo Fisher Scientific, Gilead Sciences, Pfizer, Biogen, Merck & Co, Agilent Technologies, Amgen, Qiagen, HoffmannLa Roche, Johnson & Johnson, BristolMyers Squibb, Illumina, F. HoffmannLa Roche, AbbVie

    Segments Covered

    Type, Application, Technology, End-use, Regional

    Key Market Opportunities

    Personalized medicine development, Companion diagnostics expansion, Early disease detection methods, Biomarker discovery technologies, Rising demand for liquid biopsies

    Key Market Dynamics

    Rising chronic disease prevalence, Advancements in personalized medicine, Increasing demand for companion diagnostics, Growth in biomarker-based drug development, Technological innovations in detection methods

    Countries Covered

    North America, Europe, APAC, South America, MEA

    Market Highlights

    Author
    Rahul Gotadki
    Assistant Manager

    He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

    Leave a Comment

    FAQs

    What was the market size of the Biomarkers Market by 2024?

    The Biomarkers Market was valued at 43.08 billion USD in 2024.

    What is the projected market size of the Biomarkers Market by 2035?

    By 2035, the Biomarkers Market is projected to reach a value of 85.7 billion USD.

    What is the expected CAGR for the Biomarkers Market from 2025 to 2035?

    The expected compound annual growth rate (CAGR) for the Biomarkers Market from 2025 to 2035 is 6.45%.

    Which region is expected to dominate the Biomarkers Market by 2035?

    North America is expected to dominate the Biomarkers Market with a valuation of 37.5 billion USD by 2035.

    What was the market size for Diagnostic Biomarkers in 2024?

    The market size for Diagnostic Biomarkers was 12.09 billion USD in 2024.

    Which major players are leading the Biomarkers Market?

    Key players in the Biomarkers Market include Novartis, Thermo Fisher Scientific, Gilead Sciences, and Pfizer.

    What is the expected market size for Predictive Biomarkers in 2035?

    The market size for Predictive Biomarkers is projected to reach 17.2 billion USD by 2035.

    How much was the Asia Pacific region valued in the Biomarkers Market in 2024?

    The Asia Pacific region was valued at 7.5 billion USD in the Biomarkers Market in 2024.

    What is the market size for Research Biomarkers by 2035?

    By 2035, the market size for Research Biomarkers is expected to reach 14.3 billion USD.

    What are some challenges and opportunities in the Biomarkers Market?

    Emerging trends in the Biomarkers Market present both opportunities and challenges, particularly in innovation and regulatory compliance.

    Biomarkers Market Research Report - Global Forecast till 2035 Infographic
    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Customer Stories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne Founder
    Case Study
    Chemicals and Materials